Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and Vital Therapies Inc. (NASDAQ:VTL) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

We can see in table 1 the earnings per share, gross revenue and valuation of Apellis Pharmaceuticals Inc. and Vital Therapies Inc.

Profitability

Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Analyst Ratings

The following table shown below contains the ratings and recommendations for Apellis Pharmaceuticals Inc. and Vital Therapies Inc.

Apellis Pharmaceuticals Inc.’s upside potential is 72.55% at a $45 average target price.

Insider and Institutional Ownership

Apellis Pharmaceuticals Inc. and Vital Therapies Inc. has shares held by institutional investors as follows: 66.1% and 18.7%. Apellis Pharmaceuticals Inc.’s share held by insiders are 1.6%. On the other hand, insiders held about 1.32% of Vital Therapies Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Summary

On 4 of the 7 factors Apellis Pharmaceuticals Inc. beats Vital Therapies Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

Vital Therapies, Inc., a biotherapeutic company, focuses on developing a human hepatic cell-based therapy targeting the treatment of acute forms of liver failure in the United States. Its ELAD system is an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials to allow the patientÂ’s own liver to potentially regenerate to a healthy state or to stabilize the patient until transplant. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is headquartered in San Diego, California.